Key result
MicroRNAs represent potential diagnostic biomarkers for arrhythmogenic cardiomyopathy and sudden cardiac death, requiring rigorous discovery and validation phases to confirm their clinical utility.
Why the study?
Sudden cardiac death diagnosis remains challenging with inconclusive answers, prompting interest in evaluating microRNAs as diagnostic biomarkers in arrhythmogenic cardiomyopathy.
What are the methods used for the discovery and validation of microRNAs as diagnostic biomarkers in sudden cardiac death and arrhythmogenic cardiomyopathy?
What are the methods used for the discovery and validation of microRNAs as diagnostic biomarkers in sudden cardiac death and arrhythmogenic cardiomyopathy?
MicroRNAs hold potential as diagnostic biomarkers for sudden cardiac death and arrhythmogenic cardiomyopathy, requiring rigorous discovery and validation phases.
miRNA profiling may aid biomarker discovery in forensic contexts; leaves open validation before any diagnostic adoption.
INTRODUCTION: MicroRNAs (miRNAs) are a non-coding RNA class of about 22 nucleotides that regulate gene expression by complementarily binding the 3’-untraslated regions of mRNA; thus, causing the inhibition of translation or mRNA degradation. A different expression profile of miRNAs (upregulated or downregulated) could lead to an imbalance in gene expression.EVIDENCE ACQUISITION: In recent years, many studies have focused on miRNAs and their role as biomarkers in diseases with difficult and inconclusive diagnoses. One of the most challenging diagnoses in the forensic field is sudden cardiac death (SCD) diagnosis which still has no comprehensive answers to the causes that determine the death of an apparently healthy subject.EVIDENCE SYNTHESIS: Thus, it could be interesting to study new biomarkers in genetic tests such as miRNAs. We have collected the most interesting studies in literature, focusing on the quantification methods used for the detection and validation of miRNAs with a potential role as biomarkers in arrhythmogenic cardiomyopathy, one of the most frequent pathological causes of SCD.CONCLUSIONS: In this review we will discuss the scientific logical path that starts from a discovery phase, using screening methods to select a group of differentially expressed miRNAs, up to a validation phase, which selects only informative miRNAs with a potential role as biomarkers.
No takes yet. Share an insight, caveat, or question.
Michele et al. (2024) conducted a review in Sudden cardiac death and arrhythmogenic cardiomyopathy. MicroRNAs as diagnostic biomarkers was evaluated. MicroRNAs represent potential diagnostic biomarkers for arrhythmogenic cardiomyopathy and sudden cardiac death, requiring rigorous discovery and validation phases to confirm their clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: